Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucitanib plus toripalimab in advanced recurrent or metastatic solid tumors
ChiCTR2400087935Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lucitanib and toripalimab in Nonhematologic neoplasms, nasopharyngeal carcinoma (NPC), gastric adenocarcinoma and 2 more, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Phase Ib - recommended phase II dose, Phase Ib - safety and 2 more. Started Aug 2024; status: completed.
02
Drugs
lucitanibtoripalimab
03
Conditions
Nonhematologic neoplasmsnasopharyngeal carcinoma (NPC)gastric adenocarcinomahepatocellular carcinoma (HCC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400087935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087935.